Single center experience of everolimus combined with long-acting octreotide in patients (pts) with pretreated advanced well differentiated neuroendocrine tumours (NETs) of different origin.
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Everolimus (Primary) ; Octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 01 Oct 2015 New trial record